Liberate Bio
Founded 2022 · 14 employees on LinkedIn · 1 known investors
Liberate Bio develops lipid nanoparticle (LNP) delivery technologies for in vivo cell therapies and genetic medicines, with a focus on myeloid-optimized CAR-M programs that target tissues beyond the liver. The company works on targeted nucleic acid delivery for therapeutic applications.
Founders & leadership
WS
Walter StrappsinChief Scientific Officer
Investors · 1
Competitors · 2
by search overlap
elevatebio13 shared keywordsElevateBio is a contract development and manufacturing organization (CDMO) for advanced therapies, offering discovery, process development, analytics, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA therapeutics, and gene editing. It partners with drug developers to bring cell and gene therapies from early discovery through commercial-scale cGMP manufacturing.
Bridgebio12 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Companies competing with Liberate Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Liberate Bio do?
- Liberate Bio develops lipid nanoparticle (LNP) delivery technologies for in vivo cell therapies and genetic medicines, with a focus on myeloid-optimized CAR-M programs that target tissues beyond the liver. The company works on targeted nucleic acid delivery for therapeutic applications.
- Who are Liberate Bio's investors?
- Liberate Bio's investors include Khosla Ventures.